Form 4 for MCRB Seres Therapeutics, Inc.
Accepted 2023-10-31 00:00:00 ET · period of report 2023-10-27 · accession 0000899243-23-020080 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-31 | 2023-10-27 | MCRB | Shaff Eric D. | CEO, Pres, Dir | M - OptEx | $0.00 | +27.8K | 124.2K | +29% | $0 |
| D | 2023-10-31 | 2023-10-30 | MCRB | Shaff Eric D. | CEO, Pres, Dir | S - Sale+OE | $1.35 | -8,552 | 115.6K | -7% | -$11.5K |
| D | 2023-10-31 | 2023-04-27 | MCRB | Shaff Eric D. | CEO, Pres, Dir | A - Grant | $0.00 | +55.7K | 55.7K | New | $0 |
| D | 2023-10-31 | 2023-10-27 | MCRB | Shaff Eric D. | CEO, Pres, Dir | M - OptEx | $0.00 | -27.8K | 27.8K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-27 | M | A | 27,838 | $0.00 | 124,172 | D | — | — | |
| 2 | Common | Common Stock | 2023-10-30 | S | D | 8,552 | $1.35 | 115,620 | D | — | — | (F3) The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Restricted Stock Units | 2023-04-27 | A | A | 55,675 | $0.00 | 55,675 | D | — · — to — | 55,675 Common Stock | (F1) On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. (F4) Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. |
| 4 | Derivative | Restricted Stock Units | 2023-10-27 | M | D | 27,838 | $0.00 | 27,837 | D | — · — to — | 27,838 Common Stock | (F1) On February 3, 2023, the reporting person was granted an award of 55,675 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 27,838 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 27,837 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. (F4) Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. |